Latest news with #TempusAI
Associated Press
10 hours ago
- Business
- Associated Press
TEM Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Against TEM
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ('AI') enabled precision medicine solutions. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Tempus AI, Inc. (TEM) Misled Investors Regarding its Business Prospects According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. What Now: You may be eligible to participate in the class action against Tempus AI, Inc. Shareholders who want to serve as lead plaintiff for the class should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Tempus AI, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Associated Press
18 hours ago
- Business
- Associated Press
Deadline Alert: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2025-- Glancy Prongay & Murray LLP reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM ) common stock between August 6, 2024 and May 27, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR TEMPUS INVESTMENTS, CLICKHERETO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On May 28, 2025, Spruce Point Capital published a report alleging, among other things, that Tempus' AI capabilities were overstated, and that Company's recent financial guidance revision revealed weakness in its core operations. On this news, Tempus' stock price fell $12.67, or 19.2%, to close at $53.20 per share on May 28, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; (5) the foregoing issues revealed weakness in core operations and revenue prospects; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Tempus common stock during the Class Period, you may move the Court no later than August 12, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: [email protected] Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on CONTACT: Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100 Los Angeles, CA 90067 Charles Linehan Email:[email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at: KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Glancy Prongay & Murray LLP Copyright Business Wire 2025. PUB: 06/27/2025 12:00 PM/DISC: 06/27/2025 12:00 PM
Globe and Mail
19 hours ago
- Business
- Globe and Mail
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Services segment increased 43.2% year over year to $61.9 million, driven by a 58% growth in Insights, the company's data licensing business. Gross profit outpaced revenue growth, up 65.2% with only a modest 3% increase in the cost of revenues. The business has scaled significantly, securing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics over the past year. Against that backdrop, Tempus' ability to sustain such strong growth rates in Data and Services is particularly impressive. Most of these contracts span multiple years, with total remaining contract value reflecting data and services yet to be delivered. Several recent developments are setting the stage for the momentum to continue. A major highlight is Tempus AI's $200 million data and modeling license agreement with AstraZeneca AZN and Pathos to build the world's largest foundation model, bringing AZN's total remaining contract value to over $1 billion as of April 30. AZN and Pathos are also covering a large portion of the compute costs to train the model. Notably, the agreement's non-exclusive nature allows Tempus to license data and build models with others in the future. The company also expanded its collaboration with Illumina, which will use its multimodal data platform to accelerate clinical benefits of molecular profiling across all major diseases. In May, Tempus inked a large data agreement with Boehringer Ingelheim focused on biomarker development and novel discovery efforts, building on their past collaboration. Further, the company's new oncology-focused platform, Loop, is already in use by a large pharmaceutical company to prioritize drug targets in patient subpopulations with severe unmet needs. TEM's Key Competitors in Data and Services ICON ICLR, an Ireland-based contract research organization, experienced a significant increase in overall biotech opportunities and a modest uptick in project win rates in the first quarter of 2025. However, it was ultimately offset by an increased number of customer-cancelled request for proposal (RFP) opportunities. In large pharma, RFP opportunities were softer in the quarter; still, ICLR's high success rate underscored its strong positioning as a strategic partner. IQVIA 's IQV Technology & Analytics Solutions business continued the strong recovery trend in the first quarter of 2025, with clients launching new drugs and executing their commercial roadmaps. However, IQV faced slower decision-making from clinical customers on new programs, reflecting broader macroeconomic pressure and industry caution. IQVIA reported a 10% increase in average time from RFP issuance to award in the quarter, both year over year and sequentially. TEM Outperforms Peers, Industry, But Valuation Stretched Year to date, Tempus AI shares have surged 102.5%, outperforming the industry's 18% growth and also delivering stronger returns than IQV and ICLR. Image Source: Zacks Investment Research TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.47X compared to the industry average of 5.83X. Image Source: Zacks Investment Research TEM Stock Estimate Trend As you can see, earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture. TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report ICON PLC (ICLR): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report Tempus AI, Inc. (TEM): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
3 days ago
- Business
- Yahoo
Tempus AI, Inc. (TEM): A Bull Case Theory
We came across a bullish thesis on Tempus AI, Inc. on Make Money, Make Time's Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls' thesis on TEM. Tempus AI, Inc.'s share was trading at $65.65 as of June 23rd. A healthcare professional holding a device with innovative technology developed by the medical technology company. Tempus AI (TEM) is a high-growth healthcare technology company that has captured investor attention, particularly due to its association with artificial intelligence. However, despite its positioning in the market, TEM is not yet a pure AI play, with approximately 75% of its revenue still derived from its core genomics business. While the company has a compelling long-term vision and remains high on watchlists, its current fundamentals raise concerns. TEM is unprofitable, and although it enjoys a strong retail investor base and impressive growth, this alone is not enough to justify a large investment position. Valuation remains a sticking point: the stock trades at 9.4x next-twelve-month (NTM) sales and an extremely stretched EV/EBITDA multiple of 450x. These levels suggest the stock price may have outpaced the underlying business fundamentals, fueled in part by speculative sentiment and the publicity surrounding notable investor interest, including trades linked to Nancy Pelosi. Despite these valuation concerns, TEM does exhibit several attractive characteristics—chief among them, its visionary leadership and the optionality embedded in its evolving AI-driven healthcare model. In the near term, the stock is expected to experience significant volatility, which could create tactical trading opportunities for investors. However, until profitability improves and the AI narrative becomes more embedded in its actual revenue mix, TEM remains a speculative play with more questions than answers. For now, it's a stock better suited for watchlists than core portfolios, but one that could become much more compelling as the business matures and valuation becomes more grounded in reality. Previously, we covered a on Tempus AI, Inc. by Oliver | MMMT Wealth in April 2025, which highlighted the company's diversified model, strong growth, and undervaluation at 6.0x NTM sales. The stock has appreciated approximately 52% since our coverage. The thesis still stands. In this new thesis, Oliver | MMMT Wealth emphasizes the long-term potential and warns investors about short-term volatility. Tempus AI, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held TEM at the end of the first quarter which was 17 in the previous quarter. While we acknowledge the risk and potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
7 days ago
- Business
- Business Upturn
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc. , No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (ii) the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus AI; (iii) Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (iv) AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable 'pass-through payment' via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and (v) the above issues revealed weakness in core operations and revenue prospects. The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
